Table 4.

Unstandardized parameter estimates in the linear growth model.

Variable 1		Variable 2	Estimate	S. E.	Est./S.E.	p
Intercept		PDS - Baseline	1	0	-	-
		PDS – 2 months	1	0	-	-
		PDS – 6 months	1	0	-	-
Slope		PDS – Baseline	−6	0	-	-
		PDS – 2 months	−4	0	-	-
		PDS – 6 months	0	0	-	-
Intercept	On	Consecutive Weeks Abstinent – Phase I	−0.35	0.43	−0.81	.42
		Group	−4.97	2.52	−1.97	.049*
Slope	On	Consecutive Weeks Abstinent – Phase I	−0.06	0.09	−0.68	.50
		Group	−0.56	0.54	−1.04	.30
Drug Positive Urines – Phase III	On	Intercept	0.01	0.01	1.06	.29
		Slope	0.14	0.07	1.99	.047*
		Consecutive Weeks Abstinent – Phase I	−0.17	0.03	−5.14	.00**
		Age	−0.02	0.01	−1.18	.24
		Group	0.07	0.20	0.37	.71
Consecutive Weeks Abstinent – Phase I	On	Group	0.29	0.57	.51	.61
Intercept	With	Slope	5.29	3.85	1.38	.17
Age	With	Intercept	−9.65	8.71	−1.11	.27
		Slope	3.03	1.88	1.61	.11
		Group	0.39	0.35	1.11	.27
Consecutive Weeks Abstinent – Phase I	With	Age	4.62	2.06	2.25	.03*
PDS – Baseline, 2, and 6 months		Residual Variances (constrained equal)	52.85	8.04	6.57	.00**
Consecutive Weeks Abstinent – Phase I		Residual Variance	8.21	1.14	7.18	.00**
Drug Positive Urines – Phase III		Residual Variance	0.65	0.12	5.62	.00**
Intercept		Residual Variance	85.04	21.72	3.92	.00**
Slope		Residual Variance	3.62	1.06	3.43	.00**

^*p < .05

^**p < .01